Skip to main content
Evidence Snapshot

Histamine H2 receptor

CHEMBL1941 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:38Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1941
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Histamine H2 receptor as ChEMBL target CHEMBL1941, mapped to UniProt P25021. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Histamine H2 receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1941
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P25021
Histamine H2 receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Histamine H2 receptor matters

As of 2026-09-14

Histamine H2 receptor is reviewed as Histamine H2 receptor (UniProt P25021); Histamine H2 receptor shows approved-linked disease relevance led by gastroesophageal reflux disease. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 91 approved drugs, 3142 compounds, and 500 assays, with lead potency reaching pChEMBL 9.1.

Disease context
gastroesophageal reflux disease

Histamine H2 receptor shows approved-linked disease relevance led by gastroesophageal reflux disease. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CIMETIDINE, FAMOTIDINE, LAFUTIDINE.

Start review with gastroesophageal reflux disease because it currently carries approved-linked support. Linked drugs include CIMETIDINE, FAMOTIDINE, LAFUTIDINE, NIZATIDINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 6 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 91 approved drugs, 3142 compounds, and 500 assays for this target. The dominant activity type is KI. CHEMBL194837 is the current potency anchor at pChEMBL 9.1.

Use CHEMBL194837 as the tractability anchor when discussing potency (pChEMBL 9.1).

Activity source · ChEMBL 36 via Core Engine
91 approved pChEMBL 9.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Histamine H2 receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P25021, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why gastroesophageal reflux disease is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3142
Total Compounds
500
Total Assays
91
Approved Drugs
IC50: 935.0, KI: 1530.0, EC50: 248.0, KD: 74.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL194837
 9.1 IC50 —
No preferred name
CHEMBL1627
 8.8 Ki —
No preferred name
CHEMBL5276441
 8.7 Ki —
No preferred name
CHEMBL4875600
 8.7 Ki —
No preferred name
CHEMBL5207281
 8.5 Ki —

Approved Drugs

Structure Compound First Approval
ASENAPINE MALEATE
CHEMBL3544974
 2009
PRAMIPEXOLE
CHEMBL301265
 1997
FAMOTIDINE
CHEMBL902
 1986
RANITIDINE
CHEMBL1790041
 1983
MAPROTILINE
CHEMBL21731
 1980
SULOCTIDIL
CHEMBL404849
 1979
CIMETIDINE
CHEMBL30
 1977
CLEMASTINE
CHEMBL1626
 1977
THIORIDAZINE
CHEMBL479
 1962
CYPROHEPTADINE
CHEMBL516
 1961
AMITRIPTYLINE
CHEMBL629
 1961
HISTAMINE
CHEMBL90
 1939
MIANSERIN
CHEMBL6437
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:38Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1941